Cargando…

T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis

OBJECTIVES: To develop and validate a radiomics nomogram to improve prediction of recurrence and metastasis risk in T1 stage clear cell renal cell carcinoma (ccRCC). METHODS: This retrospective study recruited 168 consecutive patients (mean age, 53.9 years; range, 28–76 years; 43 women) with T1 ccRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Bing, Sun, Cong, Gu, Hui, Yang, Shifeng, Yuan, Xianshun, Ji, Congshan, Huang, Zhaoqin, Yu, Xinxin, Duan, Shaofeng, Wang, Ximing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672185/
https://www.ncbi.nlm.nih.gov/pubmed/33251142
http://dx.doi.org/10.3389/fonc.2020.579619
_version_ 1783611077759598592
author Kang, Bing
Sun, Cong
Gu, Hui
Yang, Shifeng
Yuan, Xianshun
Ji, Congshan
Huang, Zhaoqin
Yu, Xinxin
Duan, Shaofeng
Wang, Ximing
author_facet Kang, Bing
Sun, Cong
Gu, Hui
Yang, Shifeng
Yuan, Xianshun
Ji, Congshan
Huang, Zhaoqin
Yu, Xinxin
Duan, Shaofeng
Wang, Ximing
author_sort Kang, Bing
collection PubMed
description OBJECTIVES: To develop and validate a radiomics nomogram to improve prediction of recurrence and metastasis risk in T1 stage clear cell renal cell carcinoma (ccRCC). METHODS: This retrospective study recruited 168 consecutive patients (mean age, 53.9 years; range, 28–76 years; 43 women) with T1 ccRCC between January 2012 and June 2019, including 50 aggressive ccRCC based on synchronous metastasis or recurrence after surgery. The patients were divided into two cohorts (training and validation) at a 7:3 ratio. Radiomics features were extracted from contrast enhanced CT images. A radiomics signature was developed based on reproducible features by means of the least absolute shrinkage and selection operator method. Demographics, laboratory variables (including sex, age, Fuhrman grade, hemoglobin, platelet, neutrophils, albumin, and calcium) and CT findings were combined to develop clinical factors model. Integrating radiomics signature and independent clinical factors, a radiomics nomogram was developed. Nomogram performance was determined by calibration, discrimination, and clinical usefulness. RESULTS: Ten features were used to build radiomics signature, which yielded an area under the curve (AUC) of 0.86 in the training cohort and 0.85 in the validation cohort. By incorporating the sex, maximum diameter, neutrophil count, albumin count, and radiomics score, a radiomics nomogram was developed. Radiomics nomogram (AUC: training, 0.91; validation, 0.92) had higher performance than clinical factors model (AUC: training, 0.86; validation, 0.90) or radiomics signature as a means of identifying patients at high risk for recurrence and metastasis. The radiomics nomogram had higher sensitivity than clinical factors mode (McNemar’s chi-squared = 4.1667, p = 0.04) and a little lower specificity than clinical factors model (McNemar’s chi-squared = 3.2, p = 0.07). The nomogram showed good calibration. Decision curve analysis demonstrated the superiority of the nomogram compared with the clinical factors model in terms of clinical usefulness. CONCLUSION: The CT-based radiomics nomogram could help in predicting recurrence and metastasis risk in T1 ccRCC, which might provide assistance for clinicians in tailoring precise therapy.
format Online
Article
Text
id pubmed-7672185
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-76721852020-11-26 T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis Kang, Bing Sun, Cong Gu, Hui Yang, Shifeng Yuan, Xianshun Ji, Congshan Huang, Zhaoqin Yu, Xinxin Duan, Shaofeng Wang, Ximing Front Oncol Oncology OBJECTIVES: To develop and validate a radiomics nomogram to improve prediction of recurrence and metastasis risk in T1 stage clear cell renal cell carcinoma (ccRCC). METHODS: This retrospective study recruited 168 consecutive patients (mean age, 53.9 years; range, 28–76 years; 43 women) with T1 ccRCC between January 2012 and June 2019, including 50 aggressive ccRCC based on synchronous metastasis or recurrence after surgery. The patients were divided into two cohorts (training and validation) at a 7:3 ratio. Radiomics features were extracted from contrast enhanced CT images. A radiomics signature was developed based on reproducible features by means of the least absolute shrinkage and selection operator method. Demographics, laboratory variables (including sex, age, Fuhrman grade, hemoglobin, platelet, neutrophils, albumin, and calcium) and CT findings were combined to develop clinical factors model. Integrating radiomics signature and independent clinical factors, a radiomics nomogram was developed. Nomogram performance was determined by calibration, discrimination, and clinical usefulness. RESULTS: Ten features were used to build radiomics signature, which yielded an area under the curve (AUC) of 0.86 in the training cohort and 0.85 in the validation cohort. By incorporating the sex, maximum diameter, neutrophil count, albumin count, and radiomics score, a radiomics nomogram was developed. Radiomics nomogram (AUC: training, 0.91; validation, 0.92) had higher performance than clinical factors model (AUC: training, 0.86; validation, 0.90) or radiomics signature as a means of identifying patients at high risk for recurrence and metastasis. The radiomics nomogram had higher sensitivity than clinical factors mode (McNemar’s chi-squared = 4.1667, p = 0.04) and a little lower specificity than clinical factors model (McNemar’s chi-squared = 3.2, p = 0.07). The nomogram showed good calibration. Decision curve analysis demonstrated the superiority of the nomogram compared with the clinical factors model in terms of clinical usefulness. CONCLUSION: The CT-based radiomics nomogram could help in predicting recurrence and metastasis risk in T1 ccRCC, which might provide assistance for clinicians in tailoring precise therapy. Frontiers Media S.A. 2020-11-04 /pmc/articles/PMC7672185/ /pubmed/33251142 http://dx.doi.org/10.3389/fonc.2020.579619 Text en Copyright © 2020 Kang, Sun, Gu, Yang, Yuan, Ji, Huang, Yu, Duan and Wang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kang, Bing
Sun, Cong
Gu, Hui
Yang, Shifeng
Yuan, Xianshun
Ji, Congshan
Huang, Zhaoqin
Yu, Xinxin
Duan, Shaofeng
Wang, Ximing
T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis
title T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis
title_full T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis
title_fullStr T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis
title_full_unstemmed T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis
title_short T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis
title_sort t1 stage clear cell renal cell carcinoma: a ct-based radiomics nomogram to estimate the risk of recurrence and metastasis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672185/
https://www.ncbi.nlm.nih.gov/pubmed/33251142
http://dx.doi.org/10.3389/fonc.2020.579619
work_keys_str_mv AT kangbing t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT suncong t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT guhui t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT yangshifeng t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT yuanxianshun t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT jicongshan t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT huangzhaoqin t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT yuxinxin t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT duanshaofeng t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis
AT wangximing t1stageclearcellrenalcellcarcinomaactbasedradiomicsnomogramtoestimatetheriskofrecurrenceandmetastasis